We are live on ! Find out more
RDHL

Redhill Biopharma
RDHL

Fund managers haven’t disclosed any holdings of RDHL yet.

RDHL Hedge Fund Activity: Q1 2026 in Review

16 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q1 2026, worth a combined $386K — down 25% from $514K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of RDHL and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 5 added.

The largest buyer was XTX Topco, opening a new position worth an estimated $16K. The largest seller was Yorkville Advisors Global, cutting an estimated $37.6K.

  • 16 institutional investors held Redhill Biopharma (RDHL) as of Q1 2026, down from 17 in Q4 2025.
  • Funds reported $386K of Redhill Biopharma stock for Q1 2026, down 25% quarter-over-quarter.
  • 3 funds opened new Redhill Biopharma positions in Q1 2026 and 4 closed out, a net change of -1 holder.
  • The largest Redhill Biopharma buyer in Q1 2026 was XTX Topco, an estimated $16K added.
  • The largest Redhill Biopharma seller in Q1 2026 was Yorkville Advisors Global, an estimated $37.6K sold.

Based on aggregated 13F filings for Q1 2026.